利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.038 秒)

    COMBINATION THERAPY OF 4-(CYCLOPROPYLAMINO)-2-(4-(4-(ETHYLSULFONYL)PIPERAZIN-1-YL)PHENYLAMINO)PYRIMIDINE-5-CARBOXAMIDE AND FLUDARABINE
    1.
    发明申请
    COMBINATION THERAPY OF 4-(CYCLOPROPYLAMINO)-2-(4-(4-(ETHYLSULFONYL)PIPERAZIN-1-YL)PHENYLAMINO)PYRIMIDINE-5-CARBOXAMIDE AND FLUDARABINE 审中-公开
    4-（环丙基氨基）-2-（4-（4-（乙基磺酰基）哌嗪-1-基）苯基）苯基）-5-羧酰胺和氟尿嘧啶的组合治疗

    公开(公告)号：US20130237493A1

    公开(公告)日：2013-09-12

    申请号：US13823714

    申请日：2011-09-30

    申请人： Uma Sinha ,  Anjali Pandey

    发明人： Uma Sinha ,  Anjali Pandey

    IPC分类号： A61K31/506 ,  A61K31/7076

    CPC分类号： A61K31/7076 ,  A61K31/506 ,  A61K2300/00

    摘要： The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide, or a pharmaceutically acceptable salt thereof, and fludarabine for the treatment of cell proliferative disorders, such as undesired acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL); mantle cell lymphoma, acute lymphocytic leukemia (ALL), follicular lymphoma, Burkitt's lymphoma, small Lymphocytic Lymphoma (SLL) and multiple myeloma.

    摘要翻译： 本发明涉及使用含有4-（环丙基氨基）-2-（4-（4-（乙基磺酰基）哌嗪-1-基）苯基氨基）嘧啶-5-甲酰胺或其药学上可接受的组合疗法的药物组合物和方法 其盐和氟​​达拉滨用于治疗细胞增殖性疾病，例如不期望的急性骨髓性白血病（AML），慢性淋巴细胞白血病（CLL），非霍奇金淋巴瘤（NHL），包括弥漫性大B细胞淋巴瘤（DLBCL）; 套细胞淋巴瘤，急性淋巴细胞白血病（ALL），滤泡淋巴瘤，伯基特淋巴瘤，小淋巴细胞淋巴瘤（SLL）和多发性骨髓瘤。

    Antidotes for factor Xa inhibitors and methods of using the same
    9.
    发明授权
    Antidotes for factor Xa inhibitors and methods of using the same 有权
    因子Xa抑制剂的解毒剂及其使用方法

    公开(公告)号：US09109046B2

    公开(公告)日：2015-08-18

    申请号：US13591098

    申请日：2012-08-21

    申请人： Uma Sinha ,  Genmin Lu ,  Pamela B. Conley

    发明人： Uma Sinha ,  Genmin Lu ,  Pamela B. Conley

    IPC分类号： A61K39/00 ,  C07K14/745 ,  A61K38/48 ,  A61K47/48 ,  C12N9/64

    CPC分类号： C12N9/6432 ,  A61K38/482 ,  A61K38/4826 ,  A61K38/4833 ,  A61K38/4846 ,  A61K38/4853 ,  A61K39/00 ,  A61K47/60 ,  C12Y304/21006

    摘要： The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

    摘要翻译： 本发明涉及靶向因子Xa的抗凝剂的解毒剂。 解毒剂是与因子Xa抑制剂结合的因子X和因子Xa蛋白衍生物，从而基本上中和它们，但不组装到凝血酶原酶复合物中。 本文所述的衍生物缺乏或具有降低的内在凝结剂活性。 本文公开的是使用因子Xa抑制剂正在进行抗凝治疗的患者中的抗凝，停止或预防出血的方法。

    COMBINATION THERAPY WITH 4-(3-(2H-1,2,3-TRIAZOL-2-YL)PHENYLAMINO)-2-((1R,2S)-2-AMINOCYCLOHEXYLAMINO)PYRIMIDINE-5-CARBOXAMIDE
    10.
    发明申请
    COMBINATION THERAPY WITH 4-(3-(2H-1,2,3-TRIAZOL-2-YL)PHENYLAMINO)-2-((1R,2S)-2-AMINOCYCLOHEXYLAMINO)PYRIMIDINE-5-CARBOXAMIDE 审中-公开
    与4-（3-（2H-1,2,3-三唑-2-基）苯基氨基）-2 - （（1R，2S）-2-氨基甲酰氧基]氨基）嘧啶-5-羧酰胺

    公开(公告)号：US20130244963A1

    公开(公告)日：2013-09-19

    申请号：US13823699

    申请日：2011-09-30

    申请人： Uma Sinha ,  Anjali Pandey

    发明人： Uma Sinha ,  Anjali Pandey

    IPC分类号： A61K31/506 ,  A61K45/06 ,  A61K31/704 ,  A61K31/519 ,  A61K31/573

    CPC分类号： A61K31/506 ,  A61K31/505 ,  A61K31/519 ,  A61K31/573 ,  A61K31/704 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing a SYK inhibitor, or a pharmaceutically acceptable salt thereof, and a antineoplastic or antiinflammatory agent for the treatment of inflammatory, autoimmune and cell proliferative diseases, such as allergic reaction, transplant rejection, rheumatoid arthritis (RA), lupus, multiple sclerosis (MS) or psoriasis undesired acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL) (including diffuse large B cell lymphoma (DLBCL)), mantle cell lymphoma, acute lymphocytic leukemia (ALL), follicular lymphoma, Burkitt's lymphoma, small Lymphocytic (SLL), Lymphoma, multiple myeloma, asthma, vasculitis, Idiopathic thrombocytopenic purpura (ITP), Heparin Induced Thrombocytopenia (HIT) and hemolytic anemia.

    摘要翻译： 本发明涉及药物组合物和使用含有SYK抑制剂或其药学上可接受的盐的组合疗法的药物组合物和方法，以及用于治疗炎性，自身免疫性和细胞增殖性疾病如抗过敏反应，移植物的抗肿瘤剂或抗炎剂 排斥反应，类风湿关节炎（RA），狼疮，多发性硬化症（MS）或牛皮癣不需要的急性骨髓性白血病（AML），慢性淋巴细胞性白血病（CLL），非霍奇金淋巴瘤（NHL）（包括弥漫性大B细胞淋巴瘤（DLBCL） ，淋巴细胞淋巴瘤，淋巴细胞淋巴瘤，多发性骨髓瘤，哮喘，血管炎，特发性血小板减少性紫癜（ITP），肝素诱导的血小板减少症（HIT）和溶血性贫血。